Multiple Sclerosis and Neuroinflammation Center
The UCSF Multiple Sclerosis and Neuroinflammation Center is one of California's premier programs for evaluating, diagnosing and treating adult and pediatric patients with inflammatory diseases of the nervous system. Our knowledge and expertise in caring for patients with multiple sclerosis (MS) has won us designation as a comprehensive care center and as a Partner in MS Care from the National Multiple Sclerosis Society.
Our team includes renowned experts in neurology, neuro-ophthalmology, neuropsychology, infectious disease and rehabilitative medicine. They work closely with one another, as well as with specialists in other fields, to provide personalized, comprehensive care for patients with all types of neuroinflammatory disease. The state-of-the-art tools and services of our Neurodiagnostic Center allow us to evaluate patients' conditions in great detail and use the information to design the best treatment plan for each person. The goal is to help our patients manage their symptoms and stay as active, healthy and independent as possible. The team also serves as an educational and emotional support resource for patients and their families. Telemedicine follow-up visits are available for those who find them more convenient.
While striving to deliver the best possible patient care, we also are committed to advancing medical understanding of the causes of neuroinflammatory disease and to finding potential cures. USCF is a top recipient of research funding from the National Institutes of Health and National Multiple Sclerosis Society. Our doctors have been on the forefront of research into the causes of MS and studies to develop new treatments. Dr. Stephen Hauser, director of the UCSF Weill Institute for Neurosciences, was awarded the prestigious John Dystel Prize in 2008 for his pioneering studies on genetic susceptibility to MS. Other doctors at the center have helped develop breakthrough therapies, such as the drug ocrelizumab, a treatment for progressive MS approved by the Food and Drug Administration in 2017. Our patients often have the opportunity to take part in clinical trials, studies to evaluate promising therapies.
Our center is part of the UCSF Weill Institute for Neurosciences.
Our locations
Our team
-
Riley M. Bove
MD
Neurologist -
Bruce Cree
MD, PhD, MAS
Neurologist -
Eric Fine
PhD
Neuropsychologist -
Jeffrey M. Gelfand
MD, MAS
Neurologist -
Douglas S. Goodin
MS, MD
Neurologist -
Ari J. Green
MD
Neurologist -
Joanne Guo
MD
Neurologist -
Stephen L. Hauser
MD
Neurologist -
Steve Merrill
PharmD
Pharmacist -
Sam J. Pleasure
MD, PhD
Neurologist -
Prashanth Ramachandran
MBBS
Neurologist -
Joseph Sabatino Jr.
MD, PhD
Neurologist -
Amy M. Schwartzburg
NP, MSN
Nurse practitioner -
Emmanuelle L. Waubant
MD, PhD
Neurologist -
Michael R. Wilson
MD, MAS
Neurologist -
Scott S. Zamvil
MD, PhD
Neurologist
Clinical trials
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
Comparison of intrathecal synthesis of gammaglobulins in treatment-naïve relapsing MS and clinically isolated syndrome participants before and after 3 years of treatment with ocrelizumab. Intrathecal synthesis is measured by eithe...
Recruiting
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
NEP is defined as no progression sustained for at least 24 weeks on all of the following three components (confirmed disability progression [CDP]; ≥20% increase in timed 25-foot walk test [T25FWT]; ≥20% increase in nine-hole peg t...
Recruiting
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Time to sustained disability progression is measured by the Expanded Disability Status Scale plus (EDSS+): a composite endpoint that includes EDSS change (change at any 6 month time point of > 1.0 point if baseline EDSS is < 5.5 o...
Recruiting
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
The primary objective is to evaluate the efficacy of BZA relative to placebo for reducing P100 latencies on full field transient pattern reversal visual evoked potentials (VEPs). In response to a visual stimulus, cortically genera...
Recruiting
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
To evaluate the efficacy of clemastine relative to placebo for reducing P100 latencies on full field transient pattern reversal visual evoked potentials. Measure will be reported as difference in P100 latency from baseline to 9 mo...
Recruiting
Awards & recognition
-
Best hospital in Northern California
-
Best in the U.S. in neurology & neurosurgery
Support services
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes
International Services
If you live outside the United States and are coming to UCSF for medical treatment, our patient liaisons can help coordinate all aspects of your visit.
Learn more
Interpreting Services
UCSF offers interpreters in various languages, including American Sign Language (ASL), as well as services for deaf, hard-of-hearing and visually impaired patients.
Hospital Stays
Checking into the hospital? Find helpful information by clicking on the relevant “Your Hospital Stay” booklet: Mission Bay, Parnassus or Mount
Zion.
Your Doctor Visit
See our top 10 tips for making your UCSF doctor’s appointment as stress-free and productive as possible.
Learn moreOur research initiatives
-
UCSF Multiple Sclerosis Center Research
The UCSF Multiple Sclerosis Center's research program focuses on investigating potential new treatments and improving understanding of the disease, including the effects of genes, the environment and the immune system.
